Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia

J. Michael Savoy; Mary Alma Welch; Patrice E. Nasnas; Hagop Kantarjian; Elias Jabbour

doi:10.1177/2040620718812013

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia

J. Michael Savoy, Mary Alma Welch, Patrice E. Nasnas, Hagop Kantarjian, Elias Jabbour

Leukemia

Research output: Contribution to journal › Review article › peer-review

Abstract

Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.

Original language	English (US)
Pages (from-to)	347-356
Number of pages	10
Journal	Therapeutic Advances in Hematology
Volume	9
Issue number	12
DOIs	https://doi.org/10.1177/2040620718812013
State	Published - Dec 1 2018

Keywords

Acute lymphoblastic leukemia
inotuzumab
monoclonal antibody

ASJC Scopus subject areas

Hematology

Access to Document

10.1177/2040620718812013

Cite this

@article{4c13c42980d04949b5880329972a65ee,

title = "Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia",

abstract = "Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.",

keywords = "Acute lymphoblastic leukemia, inotuzumab, monoclonal antibody",

author = "Savoy, {J. Michael} and Welch, {Mary Alma} and Nasnas, {Patrice E.} and Hagop Kantarjian and Elias Jabbour",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2018.",

year = "2018",

month = dec,

day = "1",

doi = "10.1177/2040620718812013",

language = "English (US)",

volume = "9",

pages = "347--356",

journal = "Therapeutic Advances in Hematology",

issn = "2040-6207",

publisher = "Sage Publications",

number = "12",

}

TY - JOUR

T1 - Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia

AU - Savoy, J. Michael

AU - Welch, Mary Alma

AU - Nasnas, Patrice E.

AU - Kantarjian, Hagop

AU - Jabbour, Elias

N1 - Publisher Copyright: © The Author(s), 2018.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.

AB - Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.

KW - Acute lymphoblastic leukemia

KW - inotuzumab

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85144240507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144240507&partnerID=8YFLogxK

U2 - 10.1177/2040620718812013

DO - 10.1177/2040620718812013

M3 - Review article

C2 - 33815734

AN - SCOPUS:85144240507

SN - 2040-6207

VL - 9

SP - 347

EP - 356

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

IS - 12

ER -

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this